QPPV.COM KNOWLEDGE ASSESSMENT

Zenocutuzumab: Classification, Evidence, Regulatory Status and Pharmacovigilance

Test your understanding of the concepts covered by Zenocutuzumab: Classification, Mechanism, Evidence and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which set of information is most useful to preserve for biomarker and exposure traceability?

Tumour type, stage, NRG1 fusion result, assay method where available, prior therapy and treatment exposure Only the patient’s age and the date the adverse event was reported Only the NRG1 result, because the biomarker supersedes disease and treatment history The treating site and product name, without disease or prior-treatment information

Question 2 of 10 A regulatory summary lists cholangiocarcinoma as part of the original 2024 accelerated approval. What correction is needed?

Cholangiocarcinoma was approved separately by FDA in May 2026 and should retain its distinct regulatory history Cholangiocarcinoma was included in the 2024 approval but later removed Cholangiocarcinoma was approved in 2026 only as an EU indication Cholangiocarcinoma has no FDA approval described in the article

Question 3 of 10 A reviewer sees decreased haemoglobin, sodium and platelets, and increased gamma-glutamyl transferase in a safety summary. Which interpretation is most appropriate?

These are reported laboratory abnormalities that should be interpreted in the context of advanced cancer and prior systemic treatment They establish a single characteristic mechanism of toxicity for every patient They should be disregarded because laboratory findings are not relevant to pharmacovigilance They prove that the product caused each abnormality in the pooled population

Question 4 of 10 Which statement best distinguishes the regulatory interpretation of the 2024 and 2026 indications?

All three tumour indications were granted accelerated approval under one action NSCLC and pancreatic adenocarcinoma were granted accelerated approval in 2024; cholangiocarcinoma received a separate 2026 approval not described as accelerated Cholangiocarcinoma received accelerated approval in 2024, followed by full approvals for the other tumours in 2026 The article does not distinguish regulatory pathways among the tumour types

Question 5 of 10 When reviewing suspected left-ventricular dysfunction in a heavily treated patient, which approach best reflects the article’s guidance?

Assume zenocutuzumab is the sole cause if cardiac dysfunction follows treatment Record cardiac history, prior cardiotoxic exposure, serial cardiac function, symptoms and management, while making uncertainty explicit Rely on a single ejection-fraction result because baseline information is not relevant Exclude the event from review unless a cardiac biomarker is elevated

Question 6 of 10 A treated patient develops new dyspnoea and imaging abnormalities. What is the most appropriate pharmacovigilance interpretation?

Classify the event as drug-related pneumonitis based on respiratory symptoms alone Assess for drug-related ILD or pneumonitis while documenting plausible alternatives such as infection, progression, embolism or prior radiation injury Exclude ILD because dyspnoea is also a common adverse reaction Attribute the event to tumour progression unless oxygen is required

Question 7 of 10 Which conclusion is best supported by the response-rate estimates reported for NSCLC and pancreatic adenocarcinoma?

The estimates are identical once differences in sample size are ignored The estimates describe separate tumour cohorts and should not be treated as proof of equivalent efficacy The pancreatic estimate proves superiority over the NSCLC estimate The NSCLC estimate can be applied to cholangiocarcinoma because all cohorts were biomarker-selected

Question 8 of 10 Which description best captures zenocutuzumab’s therapeutic mechanism?

A HER2/HER3 bispecific antibody that interferes with NRG1-dependent receptor activation An antibody that neutralizes NRG1 directly before it can bind either receptor A HER2-selective antibody that blocks signalling independently of HER3 A small-molecule inhibitor that suppresses all downstream kinase signalling in tumour cells

Question 9 of 10 A case report states only “NRG1-positive cancer” and provides no tumour type. Why is this information insufficient for robust pharmacovigilance review?

It prevents assessment of whether the patient received an intravenous or oral formulation It obscures indication assignment and weakens tumour-specific aggregate interpretation It makes the NRG1 result invalid in every circumstance It prevents determination of whether the reported event meets seriousness criteria

Question 10 of 10 Which statement about the eNRGy programme is best supported by the article?

It was an open-label, multicohort study, and its cohort-specific results should be interpreted separately It was a blinded randomized trial designed to compare all tumour types directly It enrolled only patients with cholangiocarcinoma It established identical response duration across all NRG1 fusion-positive cancers

Zenocutuzumab: Classification, Evidence, Regulatory Status and Pharmacovigilance

Cookie Settings